The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Whole-genome and transcriptome landscape of actionable driver-negative lung adenocarcinoma.
 
Masahiro Torasawa
No Relationships to Disclose
 
Kouya Shiraishi
No Relationships to Disclose
 
Akifumi Mochizuki
No Relationships to Disclose
 
Shingo Matsumoto
Honoraria - Amgen; AstraZeneca; Chugai Pharma; Lilly; Merck; Novartis
Research Funding - Chugai Pharma (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst)
 
Junko Hamamoto
No Relationships to Disclose
 
Hirokazu Matsushita
No Relationships to Disclose
 
Issei Imoto
No Relationships to Disclose
 
Hiroyuki Yasuda
No Relationships to Disclose
 
Kazuhisa Takahashi
Honoraria - AstraZeneca; AstraZeneca; BioMerieux Japan Ltd.; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Chugai Pharma; Daiichi Sankyo; Daiichi Sankyo; Insmed GK.; Janssen; Kyorin; Kyorin; MSD K.K; MSD K.K; Nippon Boehringer Ingelheim; Nippon Boehringer Ingelheim; Nippon Kayaku; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Sawai Pharmaceutical Co; Sawai Pharmaceutical Co; Shionogi; Shionogi; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Ono Pharmaceutical
Research Funding - Chugai Pharma; Chugai Pharma; MSD K. K.; MSD K.K; Ono Pharmaceutical; Ono Pharmaceutical
 
Yuichi Shiraishi
No Relationships to Disclose
 
Masahiro Tsuboi
Honoraria - Amgen KK; AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi-Sankyo; Johnson & Johnson; Lilly Japan; Medtronic; MSD K.K; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; AstraZeneca Japan; Chugai Pharma; MiRXES; MSD; Novartis
Research Funding - AstraZeneca Japan (Inst); Bristol-Myers Squibb KK (Inst); Johnson & Johnson/Eticon (Inst); Merck (Inst); MiRXES (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Koichi Goto
Honoraria - Amgen; Amoy Diagnostics; AstraZeneca Japan; Bristol-Myers Squibb K.K.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health; Janssen; Lilly Japan; Merck; Nippon Kayaku; Novartis; Ono Pharmaceutical; RIKEN GENESIS CO., LTD.; Sysmex; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - Amgen; Amgen; Bayer HealthCare Pharmaceuticals Inc.,; Bristol-Myers Squibb K.K.; DAIICHI SANKYO Co., Ltd.; GlaxoSmithKline K.K.; Guardant Health Japan Corp.; Haihe Biopharma Co., Ltd.; iTeos Therapeutics Inc.; Janssen; Lilly Japan; Novartis; Pharma Mar, S.A.; Syneos Health
Research Funding - Abbvie (Inst); Amgen (Inst); Amgen (Inst); AnHeart Therapeutics Inc. (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb K.K. (Inst); Chugai Pharma (Inst); CRAIF Inc. (Inst); DAIICHI SANKYO Co., Ltd. (Inst); Eisai (Inst); Guardant Health Asia, Middle East & Africa, Inc (Inst); HaiHe Biopharma Co., Ltd. (Inst); Ignyta (Inst); Janssen (Inst); Kyowa Kirin Co., Ltd. (Inst); Life Technologies (Inst); Lilly Japan (Inst); Loxo (Inst); Lunit (Inst); MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. (Inst); Merck (Inst); Merus (Inst); MSD K.K. (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Precision Medicine Asia Co., Ltd. (Inst); RIKEN GENESIS CO., LTD. (Inst); Spectrum Pharmaceuticals (Inst); Sumitomo Pharma Co., Ltd. (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Turning Point Therapeutics (Inst)
 
Shun-ichi Watanabe
No Relationships to Disclose
 
Ryuji Hamamoto
No Relationships to Disclose
 
Takashi Kohno
Consulting or Advisory Role - Lilly Japan
Speakers' Bureau - Lilly Japan; Lilly Japan
Research Funding - Chugai Pharma; Guardant Health; Konica Minolta; Sysmex
Patents, Royalties, Other Intellectual Property - Patent fee from Foundation Medicine Inc; Patent fee from Riken Genesis/Amoy Diagnostics; Patent fee from ThermoFisher Scientific